<DOC>
	<DOC>NCT01371734</DOC>
	<brief_summary>This is a double-blind study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) versus placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).</brief_summary>
	<brief_title>A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Age &gt;=7 and &lt;18 years of age Primary diagnosis of major depressive disorder (MDD) CDRSR score &gt;40 History of suicidal behavior or requires precaution against suicide Not in generally healthy medical condition History of psychosis or bipolar disorder Seizure disorder</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>MDD</keyword>
	<keyword>Depression</keyword>
</DOC>